Phase II Randomized, Sequential Group, Evaluation of Ascending Reversal Doses of PER977 Administered to Subjects With Steady State Edoxaban Dosing and Re-anticoagulation With Edoxaban Following PER977 Reversal

Trial Profile

Phase II Randomized, Sequential Group, Evaluation of Ascending Reversal Doses of PER977 Administered to Subjects With Steady State Edoxaban Dosing and Re-anticoagulation With Edoxaban Following PER977 Reversal

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Ciraparantag (Primary) ; Edoxaban
  • Indications Haemorrhage
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Perosphere
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 26 Sep 2016 Status changed from recruiting to completed.
    • 02 Sep 2015 Results presented at the ESC Congress 2015: Annual Congress of the European Society of Cardiology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top